Association between statin use and plasma d-dimer levels: A systematic review and meta-analysis of randomised controlled trials

Thrombosis and Haemostasis

Volumn 114, Issue 3, 2015, Pages 546-557

  Sahebkar, Amirhossein ^a,b   Serban, Corina ^c   Mikhailidis, Dimitri P ^d   Undas, Anetta ^e   Lip, Gregory Y H ^f   Muntner, Paul ^g   Bittner, Vera ^h   Ray, Kausik K ⁱ   Watts, Gerald F ^b   Hovingh, G Kees ^j   Rysz, Jacek ^k   Kastelein, John J P ^j   Banach, Maciej ^k  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^e JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^f UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^h University of Alabama at Birmingham   (United States)

ⁱ IMPERIAL COLLEGE LONDON   (United Kingdom)

^j ACADEMIC MEDICAL CENTER   (Netherlands)

^k MEDICAL UNIVERSITY OF LODZ   (Poland)

more..

Author keywords

Coagulation; D dimer; Fibrinolysis; Statin

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; D DIMER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; ANTICOAGULANT AGENT; BIOLOGICAL MARKER; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D;

ACUTE CORONARY SYNDROME; ARTICLE; BRAIN ISCHEMIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORONARY ARTERY DISEASE; DRUG EFFICACY; HEMODIALYSIS; HUMAN; HYDROPHILICITY; LIPOPHILICITY; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; BLOOD; BLOOD CLOTTING; DRUG EFFECTS; DYSLIPIDEMIAS; TIME FACTOR; TREATMENT OUTCOME;

ANTICOAGULANTS; BIOMARKERS; BLOOD COAGULATION; DYSLIPIDEMIAS; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 84940640322     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-11-0937     Document Type: Article

References (67)

1. Halaby R, Popma CJ, Cohen A, et al. D-Dimer elevation and adverse outcomes. J Thromb Thrombol 2015; 39: 55-59
2. Fowkes F, Housley E, Rattray A, et al. Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease. Lancet 1993; 342: 84–86
3. Smith F, Rumley A, Lee A, et al. Haemostatic factors and prediction of ischaemic heart disease and stroke in claudicants. Br J Haematol 1998; 100: 758–763
4. Lowe GD. Fibrin D-dimer and cardiovascular risk. Semin Vasc Med 2005; pp. 387–398
5. Lee AJ, Fowkes GR, Lowe GD, et al. Determinants of fibrin D-dimer in the Edinburgh Artery Study. Arterioscl Thromb Vasc Biol 1995; 15: 1094–1097
6. Schwartz RS, Borissoff JI, Spronk HM, et al. The hemostatic system as a modulator of atherosclerosis. N Engl J Med 2011; 364: 1746–1760
7. Willeit P, Thompson A, Aspelund T, et al. Hemostatic factors and risk of coronary heart disease in general populations: new prospective study and updated meta-analyses. PloS one 2013; 8: e55175
8. Cervellin G, Bonfanti L, Picanza A, et al. Relation of d-Dimer and Troponin I in Patients With New-Onset Atrial Fibrillation. Am J Cardiol 2014; 114: 1129–1130
9. Davis SJ, Kessler CM. Disseminated Intravascular Coagulation: Diagnosis and Management. Hemost Thromb 2014; 151
10. Stockley CJ, Reed MJ, Newby DE, et al. The utility of routine D-dimer measurement in syncope. Eur J Emerg Med 2009; 16: 256–260
11. Goldhaber SZ, Vaughan DE, Tumeh SS, et al. Utility of cross-linked fibrin degradation products in the diagnosis of pulmonary embolism. Am Heart J 1988; 116: 505–508
12. Stott DJ, Robertson M, Rumley A, et al. Activation of hemostasis and decline in cognitive function in older people. Arterioscl Thromb Vasc Biol 2010; 30: 605–611
13. Wilson CJ, Cohen HJ, Pieper CF. Cross-Linked Fibrin Degradation Products (D-Dimer), Plasma Cytokines, and Cognitive Decline in Community-Dwelling Elderly Persons. J Am Geriat Soc 2003; 51: 1374–1381
14. Yucel Y, Tanriverdi H, Arikanoglu A, et al. Increased fibrinogen, D-dimer and galectin-3 levels in patients with migraine. Neurol Sci 2014; 35: 545–549
15. Durczynski A, Kumor A, Hogendorf P, et al. D-dimers Revisited: A New Marker of Pancreatic Cancer. Am J Clin Oncol 2014; 37: 642
16. Inal T, Anar C, Polat G, et al. The prognostic value of D-dimer in lung cancer. Clin Resp J 2015; 9: 305-313
17. Ma X, Li Y, Zhang J, et al. Prognostic role of D-dimer in patients with lung cancer: a meta-analysis. Tumour Biol 2014; 35: 2103–2109
18. Edwards CM, Warren J, Armstrong L, et al. D-dimer: a useful marker of disease stage in surgery for colorectal cancer. Br J Surg 1993; 80: 1404–1405
19. Khangarot SS, Gupta N, Goswami B, et al. Correlation of D dimer and factor VIII levels with histopathology in patients with breast carcinoma. Cancer Biomarkers Section A 2010; 7: 305–314
20. Mitter CG, Zielinski CC. Plasma levels of D-dimer: a crosslinked fibrin-degradation product in female breast cancer. J Cancer Res Clin Oncol 1991; 117: 259–262
21. Banach M, Mikhailidis DP, Kjeldsen SE, et al. Time for new indications for statins? Medical Sci Monitor 2009; 15: MS1–5
22. Banach M, Malodobra-Mazur M, Gluba A, et al. Statin therapy and new-onset diabetes: molecular mechanisms and clinical relevance. Curr Pharmaceut Design 2013; 19: 4904–4912
23. Violi F, Calvieri C, Ferro D, et al. Statins as antithrombotic drugs. Circulation 2013; 127: 251–257
24. Phillip Owens III A, Mackman N. The Antithrombotic Effects of Statins. Ann Rev Med 2014; 65: 433–445
25. Undas A, Brummel-Ziedins KE, Mann KG. Statins and blood coagulation. Arterioscler Thromb Vasc Biol 2005; 25: 287–294
26. Margaritis M, Channon KM, Antoniades C. Statins as regulators of redox state in the vascular endothelium: beyond lipid lowering. Antioxid Redox Signal 2014; 20: 1198–1215
27. Antoniades C, Channon KM. Statins: pleiotropic regulators of cardiovascular redox state. Antioxid Redox Signal 2014; 20: 1195–1197
28. Krysiak R, Okopien B, Herman Z. Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Drugs 2003; 63: 1821–1854
29. Zhou Q, Liao JK. Pleiotropic effects of statins. – Basic research and clinical perspectives. Circulation J 2010; 74: 818–826
30. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Br Med J 2009; 339: b2535
31. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1–12
32. Moher D, Cook D, Jadad A, et al. Assessing the quality of reports of randomised trials: implications for the conduct of meta-analyses. Health Technol Assessm 1998; 3: i-iv, 1–98
33. Borenstein M, Hedges L, Higgins J, et al. Comprehensive meta-analysis version 2. Englewood, NJ: Biostat 2005: 104
34. Sutton AJ, Abrams KR, Jones DR, et al. Methods for meta-analysis in medical research, J. Wiley; 2000
35. Sahebkar A. Does PPARg2 gene Pro12Ala polymorphism affect nonalcoholic fatty liver disease risk? Evidence from a meta-analysis. DNA Cell Biol 2013; 32: 188–198
36. Sahebkar A. Are Curcuminoids Effective C-Reactive Protein-Lowering Agents in Clinical Practice? Evidence from a Meta-Analysis. Phytotherapy Res 2014; 28: 633–642
37. Song F, Altman DG, Glenny A-M, et al. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. Br Med J 2003; 326: 472
38. Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997; 50: 683–691
39. Duval S, Tweedie R. Trim and fill: a simple funnel-plot–based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000; 56: 455–463
40. Chang JW, Yang WS, Min WK, et al. Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am J Kidney Dis 2002; 39: 1213–1217
41. Dangas G, Badimon JJ, Smith DA, et al. Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. J Am Coll Cardiol 1999; 33: 1294–1304
42. Eckard AR, Jiang Y, Debanne SM, et al. Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy. J Infect Dis 2014; 209: 1156–1164
43. Kinlay S, Schwartz GG, Olsson AG, et al. Endogenous tissue plasminogen activator and risk of recurrent cardiac events after an acute coronary syndrome in the MIRACL study. Atherosclerosis 2009; 206: 551–555
44. Min L, Shao S, Wu X, et al. Anti-inflammatory and anti-thrombogenic effects of atorvastatin in acute ischemic stroke. Neural Regen Res 2013; 8: 2144
45. Sommeijer DW, MacGillavry MR, Meijers JC, et al. Anti-inflammatory and anticoagulant effects of pravastatin in patients with type 2 diabetes. Diabetes Care 2004; 27: 468–473
46. Undas A, Kaczmarek P, Sladek K, et al. Fibrin clot properties are altered in patients with chronic obstructive pulmonary disease. Thromb Haemost 2009; 102: 1176–1182
47. Van De Ree M, De Maat M, Kluft C, et al. Decrease of hemostatic cardiovascular risk factors by aggressive vs. conventional atorvastatin treatment in patients with Type 2 diabetes mellitus. J Thromb Haemost 2003; 1: 1753–1757
48. Szabo S, Suselbeck T, Borggrefe M, et al. Effect of Atorvastatin on Haemostasis, Fibrinolysis and Inflammation in Normocholesterolaemic Patients with Coronary Artery Disease. Clin Drug Invest 2010; 30: 453–460
49. Bruinstroop E, Van de Ree M, Huisman M. The use of D-dimer in specific clinical conditions: a narrative review. Eur J Intern Med 2009; 20: 441–446
50. Margetic S. Inflammation and hemostasis. Biochemia Medica 2012; 22: 49–62
51. Phipps RP, Blumberg N. Statin islands and PPAR ligands in platelets. Arterioscl Thromb Vasc Biol 2009; 29: 620–621
52. Puccetti L, Sawamura T, Pasqui A, et al. Atorvastatin reduces platelet-oxidized- LDL receptor expression in hypercholesterolaemic patients. Eur J Clin Invest 2005; 35: 47–51
53. Moraes LA, Vaiyapuri S, Sasikumar P, et al. Antithrombotic actions of statins involve PECAM-1 signalling. Blood 2013; 122: 3188–3196
54. Kaneider NC, Egger P, Dunzendorfer S, et al. Reversal of thrombin-induced deactivation of CD39/ATPDase in endothelial cells by HMG-CoA reductase inhibition effects on Rho-GTPase and adenosine nucleotide metabolism. Arterioscl Thromb Vasc Biol 2002; 22: 894–900
55. Antoniades C, Bakogiannis C, Leeson P, et al. Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling. Circulation 2011; 124: 335–345
56. Antoniades C, Bakogiannis C, Tousoulis D, et al. Preoperative atorvastatin treatment in CABG patients rapidly improves vein graft redox state by inhibition of Rac1 and NADPH-oxidase activity. Circulation 2010; 122 (11 Suppl 1): S66-S73
57. Obi C, Wysokinski W, Karnicki K, et al. Inhibition of platelet-rich arterial thrombus in vivo acute antithrombotic effect of intravenous HMG-CoA Reductase therapy. Arterioscl Thromb Vasc Biol 2009; 29: 1271–1276
58. Antonopoulos AS, Margaritis M, Lee R, et al. Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr Pharmaceut Design 2012; 18: 1519
59. Jonsdottir LS, Sigfusson N, Gunason V, et al. Do lipids, blood pressure, diabetes, and smoking confer equal risk of myocardial infarction in women as in men? The Reykjavik Study. Eur J Cardiovasc Risk 2002; 9: 67–76
60. Lowe G, Danesh J, Lewington S, et al. Tissue plasminogen activator antigen and coronary heart disease Prospective study and meta-analysis. Eur Heart J 2004; 25: 252–259
61. Folsom AR, Aleksic N, Park E, et al. Prospective Study of Fibrinolytic Factors and Incident Coronary Heart Disease The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscl Thromb Vasc Biol 2001; 21: 611–617
62. Danesh J, Whincup P, Walker M, et al. Fibrin D-dimer and coronary heart disease prospective study and meta-analysis. Circulation 2001; 103: 2323–2327
63. Bladbjerg E, De Maat M, Christensen K, et al. Genetic influence on thrombotic risk markers in the elderly–a Danish twin study. J Thromb Haemost 2006; 4: 599–607
64. Ariëns RA, de Lange M, Snieder H, et al. Activation markers of coagulation and fibrinolysis in twins: heritability of the prethrombotic state. Lancet 2002; 359: 667–671
65. Smith NL, Huffman JE, Strachan DP, et al. Genetic predictors of fibrin D-dimer levels in healthy adults. Circulation 2011; 123: 1864–1872
66. Rudnicka AR, Rumley A, Lowe GD, et al. Diurnal, seasonal, and blood-processing patterns in levels of circulating fibrinogen, fibrin D-dimer, C-reactive protein, tissue plasminogen activator, and von Willebrand factor in a 45-year-old population. Circulation 2007; 115: 996–1003
67. Tabassum F, Kumari M, Rumley A, et al. Lifecourse social position and D-dimer; findings from the 1958 British birth cohort. PLoS One 2014; 9: e93277.